Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury

Mission gains clearance from US FDA for Phase II trial of MTX562 after it receives official approval of its Investigational New Drug (IND) applicationPhase II trial expected to begin Q1 2024 in up to 160 patients with acute kidney injury (AKI) following cardiac surgeryView original content:https://www.prnewswire.co.uk/news-releases/mission-therapeutics-announces-us-fda-approval-to-initiate-phase-ii-clinical-trial-of-its-lead-asset-mtx652-in-acute-kidney-injury-302014252.html

en | boerse | 67937149 |